Brand Reference: Flexeril, Tonmya (sublingual research)
| Metric | Verified Benchmark | Source |
|---|---|---|
| Cyclobenzaprine Hydrochloride (5 mg Nocturnal Protocol) RxNorm Concept ID | 3112 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0280 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $19.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $4.70 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $5.50 / mo | 29 Zero-PHI Verified Patient Logs |
Tricyclic brainstem-acting agent reducing tonic somatic alpha- and gamma-motoneuron hyperexcitability via locus coeruleus noradrenergic and 5-HT2A antagonism, abating acute myofascial spasm and non-restorative fibromyalgia alpha-delta sleep intrusion.
For self-pay patients filling Cyclobenzaprine Hydrochloride (5 mg Nocturnal Protocol) (NDC 00378-0751-01), direct wholesale and telehealth fulfillment drops monthly spend from $19.00 retail to $4.70 (75% savings against a $0.0280 CMS pharmacy acquisition baseline).
Clinical clearance of Cyclobenzaprine Hydrochloride (5 mg Nocturnal Protocol) (Brainstem Locus Coeruleus 5-HT2A / Alpha-2 Tonic Motor Suppressant) relies on hepatic cyp3a4, cyp1a2, and cyp2d6 n-demethylation with a 18 hours half-life; patients absorbing at 33%–55% oral bioavailability typically observe target onset around 1 hour acute spasm & nocturnal relaxation.
FDA clinical labeling for Cyclobenzaprine Hydrochloride (5 mg Nocturnal Protocol) restricts administration in maoi within 14 days; acute post-mi recovery, arrhythmias, or heart failure; hyperthyroidism across 5 mg PO QHS (preferred low-sedation tier), 5 mg PO TID max 14 days acute spasm, with self-reported patient tracking dominated by next-morning hangover drowsiness at 10 mg (38% of reports), xerostomia (24% of reports).
Across 29 verified cash-pay logs, Cyclobenzaprine Hydrochloride (5 mg Nocturnal Protocol) achieves a 82.50% Worth-It rating with out-of-pocket spend averaging $5.50/mo versus $19.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 5 mg PO QHS (preferred low-sedation tier) for Cyclobenzaprine Hydrochloride (5 mg Nocturnal Protocol); monthly out-of-pocket dropped to $4.50 compared with $19.00 retail.
Completed 10 weeks on Cyclobenzaprine Hydrochloride (5 mg Nocturnal Protocol) (5 mg PO TID max 14 days acute spasm). Zero notable side effects on steady dosing.
Consistent biomarker response on 5 mg PO QHS (preferred low-sedation tier) Cyclobenzaprine Hydrochloride (5 mg Nocturnal Protocol) sourced via Cash Clinic ($5.45/mo cash pay without insurance prior authorization).